New fertility technique to be assessed by regulator

Mitochondria Mitochondria provide the energy cells need to function

Related Stories

Health Secretary Andrew Lansley has asked the Human Fertilisation and Embryology Authority to assess a controversial fertility treatment.

The "three-parent IVF" technique developed at Newcastle University involves the transfer of human genetic material between two fertilised eggs.

It could offer couples at risk of passing on serious inherited disorders a way to have a healthy child.

New legislation would be needed to allow the technique to be used.

The Newcastle University team published research last year outlining how the technique, which is aimed at helping couples affected by potentially devastating mitochondrial diseases to have healthy children, worked.

Mitochondria are found in every cell in the human body and provide the energy cells need to function.

Ethical concerns

But because mitochondrial DNA is only passed down the female line, and is not present in the nucleus of a fertilised human egg, it is possible to extract the nucleus and transplant it into a second, donor egg.

'We lost our child - and our future'

Casper Wilkes

Beth Wilkes' son Casper died from mitochondrial disease in July last year, aged three months old.

She told BBC Radio 4's Today programme: "He was born on time. It was a normal pregnancy, a straightforward labour.

"Casper passed his initial tests, and it was six weeks before we realised there was something wrong.

"He was floppy and he wasn't as responsive. He stopped crying. He just wasn't the baby we brought home from hospital.

"He endured five weeks of vigorous, invasive tests while the hospital tried to identify what was wrong."

The family eventually found out Casper had a condition called Leigh's disease.

They are now being treated by the Newcastle team as they seek to have another baby unaffected by mitochondrial disease.

The Wilkes are not receiving the technique being examined by the HFEA, but another called pre-implantation genetic diagnosis.

Mrs Wilkes says the new technique could have helped Casper.

"His eyes, face, hair would have been 100% the same. The ultimate difference it would have made is that he would have survived.

"But we not only lost our child, we lost our future."

The resulting embryo has the nuclear DNA of the mother and father, but the mitochondrial DNA of the donor.

The amount of genetic material contained in mitochondrial DNA is very small - just 13 protein-producing genes compared to the 23,000 genes inherited from parents.

But even this limited genetic relationship to a "third parent" has raised ethical concerns.

David King, head of Human Genetics Alert, said: "The more you manipulate embryos, the more risk there is."

The researchers say they are far from ready to use the technique on patients but that because the science is progressing "very rapidly", the review of the process, which would inform political debate, needs to start now.

Alison Murdoch, head of the department of reproductive medicine at Newcastle University said she anticipated the review process could take about a year.

She added: "As doctors we have a duty to treat disease and where possible to prevent disease.

"With diseases for which there are no treatments the imperative to develop new treatments is even greater.

"Of course no treatment is ever risk free and if there are risks we will need to quantify these so that doctors can discuss the relative risks and benefits with patients and their families."

The HFEA panel is set to submit its report to the government next month.

A Department of Health spokeswoman said: "This treatment is not currently possible under current legislation.

"When the group reports back and based on the evidence available, we can decide whether it is the right time to consider making these regulations."

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More Health stories



BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.